In recent years, new drugs called “biosimilars” have become available in the United States, and in the summer of 2023 at least eight new competitors to adalimumab (Humira) will be introduced. This article from the Arthritis Foundation explains how these new biologic drugs compare with existing ones, and addresses whether biosimilars should be taken during pregnancy or breastfeeding.
Mariah is a writer, patient advocate, and mom of three living with rheumatoid arthritis and Hashimoto’s thyroiditis. After learning firsthand how challenging and lonely it can be to face pregnancy and motherhood with chronic illness, Mariah became passionate about supporting women with chronic illness who are or want to become mothers. She launched Mamas Facing Forward in 2015 as a private Facebook support group, followed by this website in 2018.
